

1 **THE COST-EFFECTIVENESS OF DEPRESSION SCREENING FOR THE GENERAL**
2 **ADULT POPULATION**

3

4

5 Melike Yildirim^{1,2}, PhD, Bradley N Gaynes^{3,4}, MD, MPH, Pinar Keskinocak^{1,5}, PhD, Brian W
6 Pence⁴, PhD, Julie Swann⁶, PhD

7

8 ¹ *School of Industrial and Systems Engineering and Center for Health and Humanitarian Systems, Georgia Institute*
9 *of Technology, Atlanta, GA, USA.*

10 ² *Institute for Technology Assessment and Medical Practice Evaluation Center, Massachusetts General Hospital,*
11 *Harvard Medical School, Boston, MA, USA.*

12 ³ *Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.*

13 ⁴ *Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.*

14 ⁵ *Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.*

15 ⁶ *Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC, USA.*

16

17

18 **Corresponding Author:** Julie Swann, Ph.D., Department of Industrial and Systems
19 Engineering, North Carolina State University, Raleigh, North Carolina, USA, 111 Lampe Drive
20 CB7906, Raleigh, NC 27695. Tel.: 919-515-6423; e-mail: jlswann@ncsu.edu

21

22 **Conflicts of Interest:** None reported.

23 **Financial Support:** This research was supported in part by the Center for Health and
24 Humanitarian Systems, the William W. George Endowment at Georgia Tech, the following
25 Georgia Tech benefactors: Andrea Laliberte, Claudia L. and J. Paul Raines, and Richard E.
26 “Rick” and Charlene Zalesky, and the Allison Distinguished Professorship at NC State
27 University.

28 **Key words:** Cost-effectiveness, major depression, minor depression, routine screening,
29 incremental cost-effectiveness ratio

30

31

32

33

34

35

36

37

38

39

40

41 **ABSTRACT**

42 **Background.**

43 Depression is a treatable disease, and untreated depression can lead to serious health
44 complications and decrease the quality of life. Therefore, prevention, early identification, and
45 treatment efforts are essential. Screening has an essential role in preventive medicine in the
46 general population. Ideally, screening tools detect patients early enough to manage the disease
47 and reduce symptoms. We aimed to determine the cost-effectiveness of routine screening
48 schedules.

49 **Methods.**

50 We used a discrete-time nonstationary Markov model to simulate the progression of depression.
51 We used Monte Carlo techniques to simulate the stochastic model for 20 years or during the
52 lifetime of individuals. Baseline and screening scenario models with screening frequencies of
53 annual, 2-year, and 5-year strategies were compared based on incremental cost-effectiveness
54 ratios (ICER). Monte Carlo (MC) simulation and one-way sensitivity analysis were conducted to
55 manage uncertainties.

56 **Results.**

57 In the general population, all screening strategies were cost-effective compared to the baseline.
58 However, male and female populations differed based on cost over quality-adjusted life years
59 (QALY). Females had lower ICERs, and annual screening had the highest ICER for females,
60 with 11,134\$/QALY gained. In contrast, males had around three times higher ICER, with annual
61 screening costs of 34,065\$/QALY gained.

62 **Limitations.** We assumed that the screening frequency was not changing at any time during the
63 screening scenario. In our calculations, false-positive cases were not taking into account.

64 **Conclusions.**

65 Considering the high lifetime prevalence and recurrence rates of depression, detection and
66 prevention efforts can be one critical cornerstone to support required care. Our analysis
67 combined the expected benefits and costs of screening and assessed the effectiveness of
68 screening scenarios. We conclude that routine screening is cost-effective for all age groups of
69 females and young, middle-aged males.

70 **Key words:** Cost-effectiveness, major depression, minor depression, routine screening,
71 incremental cost-effectiveness ratio (ICER)

72

73

74 INTRODUCTION

75 Depression is one of the most common mental health conditions and a leading cause of
76 disability that results in substantial impairment (Goodwin, 2006). Both major depression and
77 minor depression present with either depressed mood or loss of interest or pleasure in usual
78 activities along with other symptoms, and the signs are present for two weeks or longer. Minor
79 depression, with a few mild symptoms, can be resolved without treatment, but it may evolve into
80 major depression. Major depression with moderate or severe symptoms significantly impacts life
81 quality and may require treatment from a mental health specialist. However, most depression
82 cases are treated in general medical settings in practice (Kessler et al., 2010).

83 On average, 22.9% of females and 15.1% of males experience at least one episode of
84 major depression in their lifetime, and 43.3% of patients are not receiving any treatment (Kessler
85 et al., 2010). Between 1999 and 2019, suicide rates, whether with an underlying diagnosis of
86 depression or not, increased by 33% in the overall population (Center for Disease Control and
87 Prevention, 2020). A 50% increase in suicide rates was observed among women from 2000 to
88 2016 (Center for Disease Control and Prevention, 2020).

89 Depression co-occurs highly with other physical illnesses, which causes health and
90 economic burdens to individuals and society. It is estimated that depression cost \$210 billion in
91 2010, including direct and indirect costs (e.g., loss of productivity) (Greenberg et al., 2015).
92 Considering high prevalence and low detection rates, improved management of disease may
93 reduce health spending and improve patients' quality and quantity of life. Due to the high cost
94 and the negative impacts on patients' overall health, improved detection efforts may be adopted
95 by policymakers and healthcare agencies.

96 Routine depression screening can be used to improve the recognition of depressive
97 episodes. In some health systems, screening is commonly used; in other settings, implementation
98 is limited (O'Connor et al., 2016). Therefore, in current clinical practice, screening measures are
99 variable. According to the National Ambulatory Medical Care Survey (NAMCS) in the United
100 States, only 2.29 percent of primary care visit patients were screened for depression in 2010
101 (National Center for Health Statistics, 2018). Whereas, in postpartum populations, screening is
102 implemented on a large scale (79%) (Sleath et al., 2007). The U.S. Preventive Services Task
103 Force (USPSTF) suggests screening of patients with a system that accurately diagnoses, treats,

104 and follows up with the patients. Still, the benefit of screening, optimal screening interval, and
105 timing is unknown (O'Connor et al., 2016; U.S. Preventive Services Task Force, 2016). Studies
106 in literature questioned the USPSTF recommendations (Thombs et al., 2012), and most of them
107 are limited to show the cost-effectiveness of routine depression screening (Valenstein et al.,
108 2001).

109 The frequency of screening of the general population in different health settings is
110 uncertain. Therefore, evaluation of medical benefits (e.g., decrease the recurrence, relapses,
111 improve treatment success and increase the symptom-free days) and costs of routine depression
112 screening strategies remain essential. In this study, we aimed to determine the cost-effectiveness
113 of routine screening schedules. We assessed the various routine screening frequencies for the
114 general population and specific age groups of females and males.

115

116 **METHODS**

117 **Model Structure**

118 A natural history model was introduced where probabilities were assigned to each health
119 state based on patient characteristics such as age, gender, and history of depression. We used a
120 discrete-time nonstationary Markov chain model, a probability distribution that changes as health
121 state, history of depression changes, and time progress. The model consists of ten health states:
122 healthy, major depression without treatment, major depression with treatment, partial remission,
123 full remission from major depression, minor depression without treatment, minor depression
124 with treatment, full remission from minor depression, suicide, and death from other causes
125 (Figure 1). States were similar to Valenstein et al.'s and others' (Ross et al., 2019; Valenstein et
126 al., 2001) model.

127 We classified the existence of 2 to 4 depressive symptoms (e.g., feelings of
128 worthlessness, loss of interest, sleep disturbance or sleeping too much, reduced appetite, fatigue)
129 as minor depression (Fils et al., 2010). We considered patients in partial remission of current
130 major depression when they have experienced the residual symptoms of the most recent episode
131 of depression (National Institute for Health and Clinical Excellence: Guidance, 2010). Healthy
132 state included individuals who were never depressed (minor or major).

133 We considered the following scenarii i) baseline (no screening), ii) annual screening, iii)
134 screening every 2 years, and iv) screening every 5 years. We evaluated the case of screening for

135 the overall population, starting at the age of 18. For screening scenarii, we assumed that the
136 screening tool could increase the probability of patients to diagnosis. We used Monte Carlo
137 techniques to simulate the stochastic model for 20 years or during the lifetime of individuals.
138 Since depression treatment generates long-term benefits, we modeled for a 20-year time horizon,
139 similar to others in the literature (Mark T. Linthicum et al., 2016; Valenstein et al., 2001).

140 We ran each scenario for 1000 replications. At the entry, patients were assigned their
141 initial states based on prevalence, and they transitioned between states at the end of each year.
142 The initial population of 100,000 individuals was introduced to the system based on U.S. age
143 distribution (Howden and Meyer, 2010) and a constant number of people preserved in the
144 system. In each time unit, the number of 18-year-old individuals entering the system was equal
145 to the number of people leaving the system from states of suicide or death from other causes. We
146 used R (version 3.6.2) in our analysis.

147

148 **Model Parameters**

149 We derived the model parameters from published data. Time-sensitive transition
150 probabilities were used, where the mortality probabilities were increased by age. We used annual
151 transitions that depend on patient histories, such as the number of previous episodes, treatment
152 status, time spent without treatment, and demographics (age, gender) if applicable. Table 1
153 shows the parameters that were used in the baseline model and their sources.

154 When there was no consensus in the literature for a parameter value, we chose
155 conservative estimates. For example, for the incidence of major depression, we used the lower
156 bound of rates reported in the ECA study (Eaton et al., 2007). Consequently, our results were not
157 biased towards screening.

158

159 *Prevalence and Incidence*

160 The ECA study's incidence rates yield a 50% lifetime prevalence of major depression
161 (Eaton et al., 1997), which is higher than reported in the literature. There are arguments around
162 the potential discordance between incidence and lifetime prevalence rates of major depression
163 (Takayanagi et al., 2014).

164 To be consistent with the reported incidence rates from national surveys, we used a lower
165 bound of incidence (Eaton et al., 2007). We integrated the matching lifetime prevalence using a

166 recall bias of 31.9% for females and 16.3% for males, and a 12-month prevalence recall bias of
167 25.5% for females and 9% for males, which were obtained from the literature (Yildirim et al.,
168 2021).

169

170 *Detection and treatment*

171 We had a detection rate of 45% for major depression and 30% for minor depression in the
172 baseline model (Valenstein et al., 2001). 43 to 60% (Kessler et al., 2010) of patients who
173 initiated the treatment from major depression depend on the age of onset, whereas 20%
174 (Valenstein et al., 2001) of cases with minor depression received treatment. The multiplication of
175 these two probabilities ((detection rate)*(initiation of treatment)) represented the transitions from
176 without treatment to with treatment state.

177 Treatment increased the full remission rate by 35% (0.37 without treatment vs. 0.50 with
178 treatment) for major depression and 29% (0.55 without treatment vs. 0.71 with treatment) for
179 minor depression (Table 1).

180 Early treatment efforts had an impact on the outcome of antidepressant treatment (Kraus et
181 al., 2019). Duration of untreated illness (DUI) longer than 6 months decreased the effect of
182 antidepressant treatment. Patients who spent more than 12 months without treatment status have
183 reduced remission likelihood by one-third (Bukh et al., 2013).

184 Transition to remission state depended on the healthcare provider and the type of treatment.
185 We assumed that 31% of major depression and 25% of minor depression cases were treated by a
186 specialist (Valenstein et al., 2001). Patients were treated with medications in primary care
187 (Valenstein et al., 2001). Whereas psychotherapy, medication, or a combination of these two was
188 used during the treatment of a specialist.

189

190 *Relapse and recurrence*

191 Major depression is a recurrent mental health condition; around 67% of patients have at
192 least one recurrence every 10 years (Solomon et al., 2000). Patients with residual symptoms were
193 3 times more likely to relapse than the fully recovered patients (0.76 from partial remission vs.
194 0.25 from full remission) (Judd et al., 1998). The number of previous episodes and treatment
195 status affected the probability of recurrences. We obtained base recurrence rates for patients who
196 had a history of cases pertaining to depression from (Solomon et al., 2000) and patients who had

197 one previous case and determined that they indicated an increased risk of recurrence by 16%
198 compared to the base. Patients with 2 or more previous episodes had an additional 32% risk of
199 recurrence (Solomon et al., 2000).

200 Patients who recovered from major remission without appropriate medication or other
201 treatments were more likely (relative risk of 1.52 to 2.69 (Gelenberg et al., 2003; Lustman et al.,
202 2006; Montgomery et al., 2004; Terra and Montgomery, 1998) for 52 weeks) to relapse. We
203 increased the recurrence rate by 30% for patients transitioning to a remission state from major
204 depression without treatment (Hansen et al., 2008).

205

206 *Suicide and Death*

207 We assumed that depression-related suicides occur only among major depressive patients
208 regardless of treatment status. We derived the transition probabilities for suicide from the
209 modifications noted in (Valenstein et al., 2001) for age and gender-specific rates. The validity of
210 suicide rates was ensured by comparing the suicide prevalence ratios from 2001 to 2018 (Center
211 for Suicide Prevention, 2020; National Institute of Mental Health, 2019). We assumed that at
212 least 50% of suicides were related to depression and 50-80% of older adults who die
213 by suicide have been shown to have major depression (Center for Suicide Prevention, 2020).

214 Age-specific death from other causes was used (Arias et al., 2017), and we assumed that
215 the major depressive patients had increased their risk of death based on other reasons by a ratio
216 of 1.58 (Cuijpers et al., 2014).

217

218 *Screening Tools*

219 For the baseline model, the detection rate of depression in usual care settings increased
220 by 50% (Valenstein et al., 2001) for major depression (baseline 45% vs. with screening 68%)
221 and 23% (Valenstein et al., 2001) for minor depression (baseline 30% vs. 37% with screening).

222

223 *Costs and Utilities*

224 We conducted our analysis from the societal perspective, which took into account direct
225 and indirect costs (Table 2). We assumed that patients who received treatment from primary care
226 settings had 4 visits plus a follow-up visit in a year (Valenstein et al., 2001). Patients treated by
227 mental health specialists had around 11 visits (Valenstein et al., 2001). 31% of patients received

228 treatment from mental health specialists (26% self-refer and 5% referred by primary care
229 physician) in a year (Valenstein et al., 2001). Additionally, 1% of patients have inpatient visits in
230 a 12-month period with an average of 11.6 days of stay. On the other hand, the cost of minor
231 depression was estimated as two-thirds of major depression (Cuijpers et al., 2007). We calculated
232 the average treatment cost of partial remission (Israel, 2010) as \$1095, based on the number of
233 remaining symptoms. We assumed there is no direct or indirect cost to capture during full
234 remission states, as for the healthy state.

235 The indirect cost was 20% lower in untreated patients (\$1600 for treated vs. \$3360 for
236 untreated). The overall cost of major depression with treatment was estimated at \$3087 vs. \$3360
237 for major depression without treatment, which was similar to the estimates from (Cuijpers et al.,
238 2007).

239 Utility estimates for all health states were obtained from the literature (Table 2). We
240 assumed that depression with and without treatment states had the same utilities.

241

242 **Incremental Cost-effectiveness Ratio (ICER)**

243 For all screening scenarii, costs and effects were compared to a situation without
244 screening. Strategies were evaluated based on the incremental cost-effectiveness ratio (ICER),
245 which was calculated as the incremental costs per incremental Quality-Adjusted Life Years
246 (QALY) gained (Equation (1)). The scenario up to the willingness-to-pay (WTP) threshold of
247 \$50 000 per additional QALY gained was classified as optimal (Cohen and Reynolds, 2008).

$$248 \quad ICER = \frac{Cost_{Screening} - Cost_{Baseline}}{QALY_{Screening} - QALY_{Baseline}} \quad (1)$$

249 **Uncertainty Analysis**

250 We performed a one-way sensitivity analysis on critical parameters (Valenstein et al.,
251 2001). We obtained all the varying values of sensitivity analysis parameters from the literature
252 (Supplementary Table S1). We used the medium and high values of incidence and prevalence
253 (Eaton et al., 2007; Kessler et al., 2010) and matched two of these with using recall bias rates
254 (Yildirim et al., 2021) for sensitivity analysis. Additionally, we tested sensitivity levels for other
255 parameters such as remission rate from major depression treatment, the utility of major
256 depression, cost of screening, treatment, and indirect costs.

257 We also performed Monte Carlo replications to report uncertainties with Bootstrapping-
258 type analysis. We calculated the average incremental cost and QALY pairs to determine which
259 proportion of ICER estimates lie below WPT, and 95% confidence intervals (CI) of ICERs.

260

261 **RESULTS**

262

263 **Screening Impact on Outcome Measures**

264 The mean duration in treatment was estimated from the simulation model as 1.26 years
265 for major depression and 1.32 months for minor depression among females. The suicide rates in
266 the baseline model were 5.11 for females and 18.08 for males per 100,000 people in a year.
267 Annual screening could prevent 24.3 cases of suicide per 10,000,000 people in a year (Table 3).
268 Annual screening also shortened the initiation of the treatment time by 5.3 (vs. 2.8 for 2-year
269 screening and 1.1 for 5-year screening) months for females and 3.2 (vs. 1.7 for 2-year screening
270 and 0.6 for 5-year screening) months for males. Annual screening increased the depression-free
271 months up to 5.5 months per year. All the screening scenarios extended time spent in remission
272 (11 days to 1.9 months for females and 7 to 29 days for males based on screening schedule).

273 Table 3 shows that, in the general population, all screening frequencies were cost-
274 effective compared with the baseline. However, there exists a difference between the male and
275 female populations based on cost-utility. Females had lower ICERs, and the annual screening
276 had the highest ratio, with \$11,134 cost per QALY gained. On the other hand, males had around
277 3 times higher ICER, with annual screening \$34,072 cost per QALY gained.

278

279 **Uncertainty Analysis**

280 ***One-way Sensitivity Analysis***

281 In our baseline analysis, we observed that screening was cost-effective for both genders
282 with low incidence and prevalence (conservative case). Consequently, the screening under
283 medium and high incidence rates was cost-effective for females and males. For females, lower
284 ICERs were observed compared to those for males.

285 Additional analysis on the other parameters such as the remission rate from major
286 depression treatment, the utility of major depression, cost of screening, treatment, and indirect
287 costs showed that female ICERs were not sensitive to any changes in these parameters. However,

288 the ICERs of the male population were higher than \$50,000 by using the upper limit of the
289 screening (Figure 2).

290 *Uncertainty among Monte-Carlo Simulations*

291 Figure S2 (in supplementary) showed every single average incremental cost and QALY
292 pairs for 1000 replications. For the female population, simulation results showed that all ICERs
293 were less than the WTP threshold of \$50,000. Additionally, less than 10 percent of simulation
294 runs for males were greater or equal to the WTP threshold in every scenario (Figure S1).

295 **Age-Specific Analysis**

296 Three different age groups, young (18-34), middle (35-64), and old (65+) were analyzed
297 by evaluating differences in cost-utilities among these subgroups; see Figure S3 (in
298 Supplementary).

299 All scenarios were cost-effective for each age group of the female population. For the
300 oldest population, about 10% of the simulations have ICERs between \$50,000 and \$75,000
301 (please see Supplementary Figure S1).

302 Young and middle age groups of the male population had ICER values up to
303 \$32,090/QALY gained. On average, screening with any frequency was not cost-effective for the
304 oldest male population.

305

306 **DISCUSSION**

307 Annual screening of all adults 18 years old or older for depression would be \$11,134 and
308 \$34,072 cost per QALY gained for females and males, respectively. In comparison, screening
309 every 5-years resulted in \$8627 cost per QALY gained for females and \$26,892 cost per QALY
310 gained for males. We found that the benefit of early detection and treatment results in the
311 improvement of QALYs. For both genders, annual screening produced greater costs. The ICER
312 decreased with increasing screening frequency for males, whereas it rose from 2-year to 5-year
313 screening in the female population.

314 In the literature, the combined results from trials showed that depression screening
315 increased the treatment rates between 2 to 50% (Pignone et al., 2002). In our model, patients
316 spent an average of 3.65 years to initiate treatment for first-onset major depression. The World
317 Health Organization's (WHO's) World Mental Health Survey showed that 35% of patients had 4
318 years of untreated time before initiating the treatment (Wang et al., 2005). We observed that

319 screening decreased the detection time up to 5 months and increased the remission time up to 1.9
320 months.

321 Based on the general intuition, depression treatments could help to improve patient's
322 mood and depressive symptoms. However, some studies showed that 10% to 30% of patients
323 experienced adverse outcomes from treatments (e.g., antidepressants) such as functional
324 impairment, poor quality of life (Al-Harbi, 2012). Therefore, we chose conservative estimates for
325 utilities. For example, we assumed that the utility of major depression with and without treatment
326 was the same. Consequently, our results were not biased towards screening.

327 The age-specific analysis showed that screening of old populations had higher ICERs
328 than the young and middle age groups. In the old male population, ICERs of all screening
329 scenarii were below the WTP threshold of \$50,000. The main reason for gender differences in
330 the cost-effectiveness of screening was the varying incidence and prevalence of major
331 depression. In literature, men had lower incidence rates than women (Eaton et al., 2007),
332 although there is concern that these rates were not reflecting the truth (Smith et al., 2018). There
333 were a couple of factors that may cause the underestimation of the rates for males. Firstly, the
334 measurement bias was observed in data because of the inadequate attendance to surveys and
335 lower primary care visits (Smith et al., 2018). Secondly, men were less likely than women to
336 have symptoms of depression that fit standard measurement tools. They experienced more
337 externalizing symptoms, such as aggression, violence, and substance abuse. Studies showed that
338 including these alternative symptoms with traditional symptoms as diagnosis criteria had
339 increased the male prevalence rates to have equal proportions with females (Martin et al., 2013).
340 We evaluated the alternative incidence, prevalence, and screening scenarii for males with the
341 same frequency as females. Our results are summarized in the Supplementary file.

342 We evaluated the external consistency of our model. By running the open network model
343 for a longer time, where new individuals were introduced into the system at the age of 18 with
344 the mortality rate, we observed that our initial distribution was equal to steady-state distribution.
345 This was the case when transient behavior was not observed in the system. To obtain a consistent
346 system, we adjusted the lifetime prevalence of major depression using reported recall bias rates
347 (Yildirim et al., 2021).

348 Interventions (e.g., training primary care physicians to better identify patients with
349 suicidal thoughts) that have an immediate cost but have gains observed during many years were

350 less cost-effective under discounting. For interventions like screening, the costs and health
351 benefits follow the same time pattern so are all affected equally by the discount factor, and the
352 relative ICER comparisons between policies are unchanged, regardless of the discounting
353 (Jamison et al., 2006). We ran additional computational results (similar to Table 3) with a
354 discount factor. In each case, the ICER that we found fell within the 95% confidence interval on
355 the ICER currently in Table 3. We also find that the relative ICER comparisons between policies
356 continue to hold, such as the cost-effectiveness of the screening for the general adult population,
357 2-year screening ICER is less (more) than 5-year screening ICER for females (males). Therefore,
358 we did not include the discount rate of utilities and costs in the body of the paper.

359 This paper evaluated the general U.S. population during the non-crises period (e.g.,
360 economic problems, or pandemics). Recent studies showed that during COVID-19, incidence
361 and prevalence were reported three times higher for moderate and severe depression (Ettman et
362 al., 2020). We further included the prevalence rate changes between 2020 and 2021 in our
363 analysis. Our results indicated that the depression screening is cost-saving for females at 2 and 5-
364 year screening frequencies and around \$11,000 to \$15,000 ICERs for males based on the
365 screening interval between 2020 to 2040 (please see Supplementary file).

366

367 **LIMITATIONS**

368 The cost-effectiveness of screening may be enhanced by targeting groups with a higher
369 incidence of depression based on ethnicity, comorbidities, or poverty level. However, we
370 analyzed screening scenarios that are valid for the general adult population. Because of incidence,
371 disease progression, and suicide rate difference between females and males, we only considered
372 the gender-specific model. We also extended our analysis for different age groups.

373 Our model did not consider the differences among the screening tools; we used average
374 test sensitivity for 9 standard screening instruments. We assumed that the screening frequency
375 was not changing at any time during the screening scenario. In our calculations, false-positive
376 cases were not taken into account.

377 We did not consider the severity of major depression; however, we included the details
378 about elevated risk based on age, gender, history of depression (major or minor), number of
379 previous episodes, remaining symptoms for onset depression, treatment status, type of treatment
380 and time spent without treatment states. We did not exclusively include medication drop-out

381 rates (transition from treatment to without treatment) in our analysis. However, the treatment
382 rates obtained from the literature implicitly include the response of adherent and non-adherent
383 patients who are not fully complied the clinical treatment guidelines.

384 Like Valenstein's model, (Valenstein et al., 2001) we assumed that suicide might happen
385 when the patient had active major depression. Patients did not have direct and indirect costs (e.g.,
386 productivity loss) when they were in full remission; however, staying there for a long time
387 decrease the risk of relapses. But distinct from their work, we used more detailed remission
388 states, e.g., partial and full remission from different types of depression. We did not consider the
389 medication costs that arose when patients were in remission. In the annual transition model,
390 patients spent at least one year in treatment when they transition to treatment states, which is
391 more than suggested acute therapy (6-12 weeks) and continuation therapy (4-8 months). We
392 assumed that patients in partial remission with residual symptoms had received maintenance
393 treatment.

394 **CONCLUSIONS**

395 Depression is a common health condition that affects an individual's everyday life.
396 Considering the high lifetime prevalence and recurrence rates of depression, detection and
397 prevention efforts play an essential role. Furthermore, the increasing trend in suicide rates
398 becomes an emerging public health problem. We conclude that routine screening is cost-
399 effective for all age groups of females and young and middle-aged males. Male population
400 results are sensitive to the higher costs of screening, which indicates that if the screening cost is
401 44% higher than the average cost, the screening of the male population is not cost-effective. Our
402 analysis combines the expected benefits and costs of screening and assesses the effectiveness of
403 screening scenarii. Screening can be one of the cornerstones to support required care. Our
404 baseline model could be used to evaluate the potential consequences of medication strategies or
405 alternative intervention scenarii.

Acknowledgements: The authors are grateful to the Editors and anonymous reviewers for their thoughtful, constructive comments.

REFERENCES

Al-Harbi, K.S., 2012. Treatment-resistant depression: therapeutic trends, challenges, and future directions. *Patient Prefer Adherence* 6, 369-388.

Arias, E., Heron, M., Xu, J., 2017. United States Life Tables, 2014. *Natl Vital Stat Rep* 66, 1-64.

Bukh, J.D., Bock, C., Vinberg, M., Kessing, L.V., 2013. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. *J Affect Disord* 145, 42-48.

Center for Disease Control and Prevention, 2020. Facts about suicide. October 22, 2021, <https://www.cdc.gov/suicide/facts/index.html>.

Center for Suicide Prevention, 2020. Depression and Suicide Prevention. February 20, 2020, <https://www.suicideinfo.ca/resource/depression-suicide-prevention/>.

Cohen, D.J., Reynolds, M.R., 2008. Interpreting the results of cost-effectiveness studies. *J Am Coll Cardiol* 52, 2119-2126.

Cuijpers, P., Smit, F., Oostenbrink, J., de Graaf, R., Ten Have, M., Beekman, A., 2007. Economic costs of minor depression: a population-based study. *Acta Psychiatr Scand* 115, 229-236.

Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., Penninx, B.W., 2014. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. *Am J Psychiatry* 171, 453-462.

Eaton, W.W., Anthony, J.C., Gallo, J., Cai, G., Tien, A., Romanoski, A., Lyketsos, C., Chen, L.S., 1997. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up. *Arch Gen Psychiatry* 54, 993-999.

Eaton, W.W., Kalaydjian, A., Scharfstein, D.O., Mezuk, B., Ding, Y., 2007. Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981-2004. *Acta Psychiatr Scand* 116, 182-188.

Ettman, C.K., Abdalla, S.M., Cohen, G.H., Sampson, L., Vivier, P.M., Galea, S., 2020. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. *JAMA Netw Open* 3, e2019686-e2019686.

Fils, J.M., Penick, E.C., Nickel, E.J., Othmer, E., Desouza, C., Gabrielli, W.F., Hunter, E.E., 2010. Minor versus major depression: a comparative clinical study. *Prim Care Companion J Clin Psychiatry* 12, PCC 08m00752.

Gelenberg, A.J., Trivedi, M.H., Rush, A.J., Thase, M.E., Howland, R., Klein, D.N., Kornstein, S.G., Dunner, D.L., Markowitz, J.C., Hirschfeld, R.M., Keitner, G.I., Zajecka, J., Kocsis, J.H., Russell, J.M., Miller, I., Manber, R., Arnow, B., Rothbaum, B., Munsaka, M., Banks, P., Borian, F.E., Keller,

M.B., 2003. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. *Biol Psychiatry* 54, 806-817.

Goodwin, G.M., 2006. Depression and associated physical diseases and symptoms. *Dialogues Clin Neurosci* 8, 259-265.

Greenberg, P.E., Fournier, A.A., Sisitsky, T., Pike, C.T., Kessler, R.C., 2015. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). *J Clin Psychiatry* 76, 155-162.

Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., Lohr, K., 2008. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. *Psychiatr Serv* 59, 1121-1130.

Howden, B., Meyer, J.A., 2010. Age and Sex Composition: 2010. October 27, 2021, <https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf>.

Israel, J.A., 2010. The Impact of Residual Symptoms in Major Depression. *Pharmaceuticals (Basel)* 3, 2426-2440.

Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., Musgrove, P., 2006. *Priorities in Health*.

Judd, L.L., Akiskal, H.S., Maser, J.D., Zeller, P.J., Endicott, J., Coryell, W., Paulus, M.P., Kunovac, J.L., Leon, A.C., Mueller, T.I., Rice, J.A., Keller, M.B., 1998. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. *J Affect Disord* 50, 97-108.

Kessler, R.C., Birnbaum, H., Bromet, E., Hwang, I., Sampson, N., Shahly, V., 2010. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). *Psychol Med* 40, 225-237.

Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C.A., Jr., Kasper, S., 2019. Prognosis and improved outcomes in major depression: a review. *Transl Psychiatry* 9, 127.

Lustman, P.J., Clouse, R.E., Nix, B.D., Freedland, K.E., Rubin, E.H., McGill, J.B., Williams, M.M., Gelenberg, A.J., Ciechanowski, P.S., Hirsch, I.B., 2006. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 63, 521-529.

Mark T. Linthicum, M.P.P., Yuri Sanchez Gonzalez, P., Karen Mulligan, P., Gigi A. Moreno, P., David Dreyfus, D.B.A., Timothy Juday, P., Steven E. Marx, P., Darius N. Lakdawalla, P., Brian R. Edlin, M.D., Ron Brookmeyer, P., 2016. Value of Expanding HCV Screening and Treatment Policies in the United States. *The American Journal of Managed Care* 22.

Martin, L.A., Neighbors, H.W., Griffith, D.M., 2013. The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. *JAMA Psychiatry* 70, 1100-1106.

Montgomery, S.A., Entsuah, R., Hackett, D., Kunz, N.R., Rudolph, R.L., Venlafaxine 335 Study, G., 2004. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. *J Clin Psychiatry* 65, 328-336.

National Center for Health Statistics, 2018. NAMCS and NHAMCS Web Tables. October 27, 2021, https://www.cdc.gov/nchs/ahcd/web_tables.htm.

National Institute for Health and Clinical Excellence: Guidance, 2010. Depression: The Treatment and Management of Depression in Adults (Updated Edition). October 27, 2021, <https://www.ncbi.nlm.nih.gov/pubmed/22132433>.

National Institute of Mental Health, 2019. Suicide. February 24, 2020, <https://www.nimh.nih.gov/health/statistics/suicide.shtml>.

O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C., Burda, B.U., Henderson, J.T., Bigler, K.D., Whitlock, E.P., 2016. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Depression in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force.

Pignone, M.P., Gaynes, B.N., Rushton, J.L., Burchell, C.M., Orleans, C.T., Mulrow, C.D., Lohr, K.N., 2002. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 136, 765-776.

Ross, E.L., Vijan, S., Miller, E.M., Valenstein, M., Zivin, K., 2019. The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. *Ann Intern Med* 171, 785-795.

Sleath, B.L., Thomas, N., Jackson, E., West, S.L., Gaynes, B.N., 2007. Physician reported communication about depression and psychosocial issues during postpartum visits. *N C Med J* 68, 151-155.

Smith, D.T., Mouzon, D.M., Elliott, M., 2018. Reviewing the Assumptions About Men's Mental Health: An Exploration of the Gender Binary. *American journal of men's health* 12, 78-89.

Solomon, D.A., Keller, M.B., Leon, A.C., Mueller, T.I., Lavori, P.W., Shea, M.T., Coryell, W., Warshaw, M., Turvey, C., Maser, J.D., Endicott, J., 2000. Multiple recurrences of major depressive disorder. *Am J Psychiatry* 157, 229-233.

Takayanagi, Y., Spira, A.P., Roth, K.B., Gallo, J.J., Eaton, W.W., Mojtabai, R., 2014. Accuracy of reports of lifetime mental and physical disorders: results from the Baltimore Epidemiological Catchment Area study. *JAMA Psychiatry* 71, 273-280.

Terra, J.L., Montgomery, S.A., 1998. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. *Int Clin Psychopharmacol* 13, 55-62.

Thombs, B.D., Coyne, J.C., Cuijpers, P., de Jonge, P., Gilbody, S., Ioannidis, J.P.A., Johnson, B.T., Patten, S.B., Turner, E.H., Ziegelstein, R.C., 2012. Rethinking recommendations for screening for depression in primary care. *CMAJ* 184, 413-418.

U.S. Preventive Services Task Force, 2016. Depression in Adults: Screening. October 27, 2021, <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screening>.

Valenstein, M., Vijan, S., Zeber, J.E., Boehm, K., Buttar, A., 2001. The cost-utility of screening for depression in primary care. *Ann Intern Med* 134, 345-360.

Wang, P.S., Berglund, P., Olfson, M., Pincus, H.A., Wells, K.B., Kessler, R.C., 2005. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62, 603-613.

Yildirim, M., Gaynes, B.N., Keskinocak, P., Pence, B.W., Swann, J., 2021. DIP: Natural history model for major depression with incidence and prevalence. *J Affect Disord* 296, 498-505.

Figure 1. Markov Health State Model




Table 1. Major and minor depression parameters

Major Depression					
Definition	Probability	Age Group	Gender-specific	Related States or Transitions	Reference
Point Prevalence %					
Major depression without treatment: -18-34 ^a -35-49 ^b -50-64 ^c -65+ ^d	Female: 10.72 ^a , 8.91 ^b , 7.17 ^c , 2.92 ^d Male: 5.08 ^a , 5.22 ^b , 4.3 ^c , 0.85 ^d	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Major depression with treatment: -18-34 ^a -35-49 ^b -50-64 ^c -65+ ^d	Female: 6.28 ^a , 5.22 ^b , 4.2 ^c , 1.71 ^d Male: 2.77 ^a , 2.85 ^b , 2.35 ^c , 0.46 ^d	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Partial remission	3	No	No	25	Assumed
Full remission: -18-34 ^a -35-49 ^b -50-64 ^c -65+ ^d	Female: 9.09 ^a , 19.14 ^b , 20.59 ^c , 24.71 ^d Male: 7.93 ^a , 11.71 ^b , 11.56 ^c , 14.76 ^d	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Death from other causes	Female: 0.16, Male: 0.17	No	Yes	25	(Arias et al., 2017)
Suicide	Female: 0.000486, Male: 0.00189	No	Yes	25	(National Institute of Mental Health, 2019)
Incidence					
Major depression among never depressed patients: -18-29 ^a -30-44 ^b -45-64 ^c -65+ ^d	Female: 0.0019 ^a , 0.0045 ^b , 0.0011 ^c , 0.0002 ^d Male: 0.0002 ^a , 0.002 ^b , 0.0001 ^c , 0.00004 ^d	Yes	Yes	2	(Eaton et al., 2007)
Major depression in patients with minor depression	0.127	No	No	4	(Tuithof et al., 2018) (Frank et al., 2002) (Hermens et al., 2004) (Broadhead et al., 1990)
Recurrence					
Recurrence of major depression (History = 1 previous episodes): -18-24 ^a -25-34 ^b -35-44 ^c -45+ ^d	Female: 0.29 ^a , 0.24 ^b , 0.29 ^c , 0.26 ^d Male: 0.35 ^a , 0.22 ^b , 0.23 ^c , 0.08 ^d	Yes	Yes	23	Calculated from (Kessler et al., 1994) and (Solomon et al., 2000)

- History = 2 previous episodes	Increased 0.16	No	No		(Solomon et al., 2000)
- History >= 3 previous episodes	Increased 0.32	No	No		(Solomon et al., 2000)
- From without treatment state risk multiplier	1.3	No	No		(Hansen et al., 2008)
Relapse from partial remission	0.76		No	19	(Paykel, 2008)
Recovery from partial remission	0.22	No	No	21	(Brodaty et al., 1993)
Recurrence from minor remission	0.055	No	No	9	Assumed
Treatment					
Initiation of treatment: -18-34 ^a -35-49 ^b -50-64 ^c -65+ ^d	0.451 ^a , 0.602 ^b , 0.5071 ^c , 0.433 ^d	Yes	No	12	Calculated (Kessler et al., 2010), (Valenstein et al., 2001)
Detection of disease	Without screening 0.45, with screening 0.68	No	No	12	(Valenstein et al., 2001)
Without care full remission	0.37	No	No	13	(Whiteford et al., 2013)
Without care partial remission	0.1	No	No	11	(Goldberg et al., 1998)
In usual care full remission	0.503	No	No	16	(Judd et al., 1998)
Duration of untreated illness (DUI) >= 12 mo. (to reach full remission) risk multiplier	1.3	No	No		(Bukh et al., 2013)
In usual care partial remission: -18-39 ^a -40-59 ^b -60+ ^c	0.21 ^a , 0.29 ^b , 0.24 ^c	Yes	No	18	(Judd et al., 1998), (Brodaty et al., 1993)
Mortality					
Mortality rate for general population	Refer for full list	20 to 100	Yes	24	(Arias et al., 2017)
Mortality risk multiplier	1.58	No	No		(Cuijpers et al., 2014)
Suicide: -18-34 ^a -35-54 ^b -55-64 ^c -65+ ^d	Female: 0.0001375 ^a , 0.0001 ^b , 0.000575 ^c , 0.0032 ^d Male: 0.0003875 ^a , 0.00204 ^b , 0.0022 ^c , 0.0038 ^d	Yes	Yes	14, 17	(National Institute of Mental Health, 2019; Valenstein et al., 2001)
Minor Depression					
<u>Definition</u>	<u>Probability</u>	<u>Age Group</u>	<u>Gender-specific</u>	<u>Related States or Transitions</u>	<u>Reference</u>

Point Prevalence (%)					
Minor depression	5.86	No	No	25	(Rodriguez et al., 2012)
Depression without treatment	5.494	No	No	25	(Kessler et al., 1997)
Minor depression with treatment	0.366	No	No	25	(Kessler et al., 1997)
Full remission	13	No	No	25	(Kessler et al., 1997)
Incidence					
Minor depression among never depressed patients	0.0087	No	No	1	(Tuithof et al., 2018)
Minor depression among major depressive patients	0.040	No	No	10	(Forsell, 2007)
Minor depression among partial remission	0.019	No	No	20	(Forsell, 2007)
Minor depression among full remission from major depression patients	0.03	No	No	22	Assumed
Recurrence					
Recurrence of Minor depression	0.16	No	No	8	(Broadhead et al., 1990) (Hermens et al., 2004)
Treatment					
Initiation of treatment	0.2	No	No	3	(Valenstein et al., 2001)
Detection of disease	Without screening: 0.3, with screening: 0.37	No	No	3	(Valenstein et al., 2001)
Without care full remission	0.55	No	No	5	(Frank et al., 2002)
In usual care full remission	0.714	No	No	7	(Hermens et al., 2004), (Broadhead et al., 1990), (Alexopoulos et al., 2009), (Frank et al., 2002), (Ceroni et al., 2002)

Table 2. Cost and utilities for each health state.

COSTS			
Variable	Description	Point Estimate (\$)	Reference
Initial visit to primary care physician		45.85	(Valenstein et al., 2001)
Administration of screening cost		4.88	(Valenstein et al., 2001)
Screening cost		50.73	(Valenstein et al., 2001)
Treatment of depression in primary care settings	4 visits and follow-up visits in a year	398.72	(Valenstein et al., 2001)
Treatment of depression by mental health specialist	11 visit/year	1020.14	(Valenstein et al., 2001)
Medication cost (outpatient)		677.16	(Valenstein et al., 2001)
Hospitalization cost	Average length of stay 11.61 days	11610	(Valenstein et al., 2001)
Physician professional fees (hospital)	Daily inpatient physician visits (based on average length of stay)	878.99	(Valenstein et al., 2001)
Medication in hospital	Based on average length of stay	21.83	(Valenstein et al., 2001)
Indirect cost of major depression	Extrapolated from lost workdays of treated and untreated patients with major depression 1 year	1600 for patients receiving treatment; 3360 for patients not receiving treatment	(Valenstein et al., 2001)
Minor depression with treatment	2/3 of major depression cost	2141	(Cuijpers et al., 2007)
Minor depression without treatment	Indirect cost	2101	(Cuijpers et al., 2007)
Partial remission	on average 2-3 symptoms	1095	(Cuijpers et al., 2007), (Israel, 2010)
UTILITIES			
State	Description	Utilities	Reference
Major depression	Same for with and without treatment	0.63	(Valenstein et al., 2001)

Minor depression, partial remission	Same for with and without treatment	0.7	(Valenstein et al., 2001)
Full remission	Same for full remission from minor and major depression	0.89	(Valenstein et al., 2001)

Table 3. Cost-effectiveness measures of screening scenarios (average of 1000 replications)

<i>Scenario</i>	<i>Costs,\$</i>	<i>QALYs</i>	<i>ICER Cost/QALY gained, compared to Baseline (95% CI)*</i>	<i>Average Annual Depression- related Suicides (/100,000)</i>	<i>Total Depressive Time (yr)</i>	<i>Minor Depression without Treatment Time (yr)</i>	<i>Minor Depression with Treatment Time (yr)</i>	<i>Major depression without Treatment Time (yr)</i>	<i>Major depression with Treatment Time (yr)</i>	<i>Total Remission Time (Full, Partial, Minor or Major) (yr)</i>
FEMALE										
Baseline	\$14,317	18.265	Reference	5.107	7.23	2.61	0.11	3.26	1.26	6.84
5-year	\$14,391	18.274	\$8627 (\$1428 – \$13,151)	5.086	7.13	2.54	0.11	3.17	1.31	6.87
2-year	\$14,503	18.287	\$8600 (\$3750 – \$14,705)	5.065	7.01	2.50	0.12	3.03	1.36	6.93
Annual	\$14,751	18.304	\$11,134 (\$7872 – \$25,500)	5.036	6.77	2.43	0.13	2.82	1.40	7.00
MALE										
Baseline	\$8864	18.963	Reference	18.078	5.95	2.93	0.14	2.05	0.84	5.72
5-year	\$9002	18.969	\$26,913 (\$11,321 – \$41,375)	18.036	5.86	2.84	0.14	2.00	0.88	5.74
2-year	\$9213	18.975	\$29,768 (\$18,647 – \$43,458)	18.026	5.78	2.83	0.15	1.91	0.88	5.76
Annual	\$9587	18.985	\$34,072 (\$27,185 – \$49,669)	17.906	5.60	2.74	0.17	1.78	0.92	5.80

CI: Confidence interval

ICER: Incremental cost-effectiveness ratio

SE: Standard error

*95% confidence interval calculated based on bootstrapping method